Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 5, 2024

Natera to Report its Second Quarter 2024 Results on August 8, 2024

July 29, 2024

New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma

July 25, 2024

Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy

July 2, 2024

Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

June 26, 2024

Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

June 16, 2024

Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 2, 2024

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

May 29, 2024

Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

May 22, 2024

Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

May 22, 2024

Natera Reports First Quarter 2024 Financial Results

May 8, 2024

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

May 2, 2024

Natera to Report its First Quarter 2024 Results on May 9

April 30, 2024

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

April 30, 2024

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

April 21, 2024

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

April 10, 2024

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

April 7, 2024

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 4, 2024

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

March 31, 2024

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

March 17, 2024

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

March 13, 2024

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

March 11, 2024

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

March 6, 2024

Natera to Participate in March Investor Conferences

February 28, 2024

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

February 26, 2024

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

February 25, 2024

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

February 19, 2024

New Study Validates Signatera™ in Endometrial Cancer

February 4, 2024

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

January 29, 2024

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties

January 28, 2024

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

January 24, 2024

Natera Acquires Reproductive Health Assets from Invitae

January 21, 2024

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

January 17, 2024

Natera Provides Update on Ravgen Trial

January 15, 2024

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

January 8, 2024

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 28, 2023

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

December 26, 2023

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

December 20, 2023

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

December 10, 2023

Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

December 5, 2023

Natera Announces Real-World Data Collaboration with Merck

November 13, 2023

Natera Reports Third Quarter 2023 Financial Results

November 7, 2023

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

November 7, 2023

Natera to Participate in November Investor Conferences

November 6, 2023

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

November 1, 2023

Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

October 21, 2023

Natera to Report its Third Quarter 2023 Results on November 8

October 19, 2023

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

October 18, 2023

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

October 15, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.